अApnaFunda
Menu

DR REDDYS LABORATORIES LTD (DRREDDY)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.48 / 100
Profitability 39Growth 33Balance sheet 72
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.55 / 100
Price 90Earnings 6FII/DII 67

Passes these screensNear 52-week high

Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹1,385 latest close · +0.8% over the last 90 sessions

₹1,200₹1,300₹1,400Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹1,200₹1,300₹1,400Jul 3Sep 4Nov 9

₹1,385 month-end · +10.0% over 12 months

₹1,200₹1,300₹1,400Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹1,200₹1,300₹1,400Nov '25May '26Nov '26

₹1,385 month-end · +19.6% over 3 years

₹1,100₹1,200₹1,300₹1,400Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹1,100₹1,200₹1,300₹1,400Nov '23May '25Nov '26

₹1,385 month-end · +154.5% since Jan '19

₹500₹1,000Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹500₹1,000Jan '19Dec '22Nov '26

52-week range ₹1101.00 to ₹1414.90 · 1-year volatility 24.1%

Was the rally earned?

+10%share price, 1 yearMultiple-driven

Partly.

  • Most of the rise came from investors paying a higher multiple (P/E 18.5x to 35.9x); per-share earnings took off 59 points.
  • The share count barely moved.
Net profit growth: −61 pts. Points of the price return explained by net profit growing (or shrinking).−61 ptsNet profit growthP/E change: +70 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+70 ptsP/E changeShare count change: +1 pts. Points of the price return explained by the share count changing. More shares count against the price.+1 ptsShare count changeShare price: +10%+10%Share priceNet profit growth: −61 pts. Points of the price return explained by net profit growing (or shrinking).−61ProfitP/E change: +70 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+70P/EShare count change: +1 pts. Points of the price return explained by the share count changing. More shares count against the price.+1SharesShare price: +10%+10%Share price
Net profit growth-61 ptsNet profit fell about 44%, which lowers the price.
P/E change+70 ptsThe P/E rose from 18.5x to 35.9x, which lifts the price.
Share count change+1 ptsShare count was little changed. More shares would count against the price.
+20%share price, 3 yearsMultiple-driven

Partly.

  • Most of the rise came from investors paying a higher multiple (P/E 21.4x to 35.9x); per-share earnings took off 37 points.
  • The share count barely moved.
Net profit growth: −37 pts. Points of the price return explained by net profit growing (or shrinking).−37 ptsNet profit growthP/E change: +57 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+57 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +20%+20%Share priceNet profit growth: −37 pts. Points of the price return explained by net profit growing (or shrinking).−37ProfitP/E change: +57 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+57P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +20%+20%Share price
Net profit growth-37 ptsNet profit fell about 28%, which lowers the price.
P/E change+57 ptsThe P/E rose from 21.4x to 35.9x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+48%share price, 5 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 61 points, but investors now pay less per rupee of profit (P/E 39.8x to 35.9x), which took 13 points back.
  • The share count barely moved.
Net profit growth: +61 pts. Points of the price return explained by net profit growing (or shrinking).+61 ptsNet profit growthP/E change: −13 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−13 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +48%+48%Share priceNet profit growth: +61 pts. Points of the price return explained by net profit growing (or shrinking).+61ProfitP/E change: −13 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−13P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +48%+48%Share price
Net profit growth+61 ptsNet profit rose about 65%, which lifts the price.
P/E change-13 ptsThe P/E fell from 39.8x to 35.9x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-33.3%recovered 2023-07
1-year volatility24.1%annualised
Beta vs sector index0.723-year daily, correlation 0.49
Volume spikes3last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−10%−20%−30%2020202120222023202420252026−31.3% 0%−10%−20%−30%2020202220242026−31.3%
Largest drawdowns

-33.3% (2021-07 peak to 2022-03 low, recovered 2023-07)

-23.0% (2024-08 peak to 2025-04 low, not yet recovered)

-22.2% (2021-01 peak to 2021-03 low, recovered 2021-06)

Most recent volume spikes

2026-10-26: 6.1x the 50-day median, price +6.6% that day

2026-07-10: 5.1x the 50-day median, price -2.0% that day

2026-07-09: 5.3x the 50-day median, price -5.9% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

35.9xP/E todayWithin its usual range
Against its own history73rd percentile
CheapestMedian 26.6xDearest

Usual range 18.6x to 42.1x since 2019-01.

Against Health Technology35.9x vs 37.0x
This company
35.9x
Sector median
37.0x

Close to the Health Technology median.

16.7x28.3x39.9x51.4xJan '19Aug '20Mar '22Oct '23May '25Nov '2616.7x28.3x39.9x51.4xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE45th▼ 34 pts vs a year ago
  • Op. margin34th▼ 42 pts vs a year ago
  • Revenue growth14th▼ 59 pts vs a year ago
  • EPS growth16th▼ 30 pts vs a year ago
  • Debt/equity ↓55th▼ 3 pts vs a year ago
  • Cash cycle ↓26th▲ 11 pts vs a year ago
  • P/E ↓54th▼ 30 pts vs a year ago
  • 12M momentum53rd▼ 24 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~17%annual earnings growth implied by the priceBelow delivered growth

At normalised P/E (five-year average earnings) of 25.8x, a holder earning 12%/yr needs earnings to grow about 17.3%/yr for 10 years, then trade at 15x.

Delivered20.5%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg
Gap−3.1 ptsimplied minus delivered
Rank591stmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

-5%11%27% Jan 2019Nov 2026 -5%11%27% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x18.8%19.8%20.9%
15x16.3%17.3%18.4%
20x13.1%14.1%15.1%

Drag a slider to test other assumptions

Implied: 17.3%/yr

Looking back

  • Jan 2020Price implied 19%/yr; EPS has since grown 11%/yr (7.0 yrs)
  • Jan 2021Price implied 24%/yr; EPS has since grown 13%/yr (6.0 yrs)
  • Jan 2022Price implied 24%/yr; EPS has since grown 16%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹1385.00
P/E
35.9x
ROCE
13.0%
Market Cap
₹1.16L cr
Revenue (TTM)
₹33227 cr
P/S
3.5x
P/B
3.1x
ROE
8.5%
Operating Margin
11.0%
Debt / Equity
0.2x
Promoter Holding
26.6%
12M Momentum
10.0%

52-week range

₹1101.00₹1414.90
90% of the way from its 52-week low to its high

Price risk

1Y volatility
24.1%
Beta vs sector
1-year daily
0.76

Balance sheet & cash

Interest cover
operating profit ÷ interest
10.7x
Cash from profit, 3Y
operating cash flow ÷ net profit
0.96x
Share count, 1Y
+1.2%

Are profits backed by cash?

6 of 7checks within range1 beyond a threshold
Other income reliance36%Beyond threshold

Other income as a share of pre-tax profit (trailing twelve months): 35.6%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate23%Within range

Median quarterly effective tax rate over about 2.5 years: 23.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.96xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 0.96x (cash from operations ₹14,860 cr, net profit ₹15,461 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+5 daysWithin range

Debtor days are above the median of the previous three fiscal years by 5 days (110 vs 105). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress7% of fixed assetsWithin range

Capital work-in-progress is 7% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-25 days / 2 yrsWithin range

Days payable changed by -25 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, DIIs added 10.7 pts; FIIs trimmed 7.5 pts.
  • The number of shareholders rose from 2.4 lakh to 4.5 lakh (+83%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters26.7%26.6%0.0 pts
FIIs28.2%20.7%-7.5 pts
DIIs21.0%31.8%+10.7 pts
Public and others23.9%20.8%-3.2 pts

Number of shareholders

4.5 lakhshareholders+83% since Sep '23
2.4L3.2L3.9L4.6L Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 2.4 lakh
Dec '23: 2.6 lakh
Mar '24: 2.6 lakh
Jun '24: 2.7 lakh
Sep '24: 3.1 lakh
Dec '24: 4.0 lakh
Mar '25: 4.6 lakh
Jun '25: 4.5 lakh
Sep '25: 4.5 lakh
Dec '25: 4.6 lakh
Mar '26: 4.5 lakh
Jun '26: 4.5 lakh
 2.4L3.2L3.9L4.6L Sep '23Sep '24Sep '25Jun '26
Sep '23: 2.4 lakh
Dec '23: 2.6 lakh
Mar '24: 2.6 lakh
Jun '24: 2.7 lakh
Sep '24: 3.1 lakh
Dec '24: 4.0 lakh
Mar '25: 4.6 lakh
Jun '25: 4.5 lakh
Sep '25: 4.5 lakh
Dec '25: 4.6 lakh
Mar '26: 4.5 lakh
Jun '26: 4.5 lakh

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−4.5%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like DR REDDYS LABORATORIES LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −19% to +6% vs the market, against −2% for all non-financial companies in the same months.
  • The gap against the base rate (−2.9%, 80% range −9.1% to +1.8%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
SYMPHONY · Feb 2023: −49.3% vs market
TATACHEM · Jan 2020: −46.5% vs market
DEEPAKNTR · Jul 2024: −36.8% vs market
SHREECEM · Feb 2023: −34.5% vs market
DALBHARAT · Mar 2023: −33.6% vs market
CCL · Apr 2023: −33.5% vs market
SYNGENE · Apr 2023: −31.1% vs market
WIPRO · Jan 2025: −26.5% vs market
CROMPTON · Aug 2024: −25.0% vs market
SUNDRMFAST · Jun 2023: −24.1% vs market
AMBUJACEM · Mar 2021: −21.6% vs market
CONCOR · Oct 2022: −21.4% vs market
LUPIN · Apr 2020: −19.8% vs market
BALKRISIND · Sep 2023: −17.8% vs market
GODREJCP · May 2023: −16.4% vs market
BAJAJELEC · Jun 2023: −15.4% vs market
TATACONSUM · Feb 2024: −14.5% vs market
RELIANCE · May 2022: −14.1% vs market
ULTRACEMCO · Mar 2023: −13.9% vs market
HEROMOTOCO · Jun 2022: −10.7% vs market
RADICO · Feb 2023: −9.5% vs market
ALKEM · Nov 2023: −7.6% vs market
CIPLA · Oct 2022: −6.4% vs market
SRF · Jan 2025: −5.5% vs market
ATUL · Apr 2025: −5.3% vs market
ENDURANCE · Jun 2025: −3.7% vs market
SIEMENS · Feb 2023: −3.5% vs market
ZYDUSLIFE · Feb 2024: −3.0% vs market
TECHM · Jan 2025: −0.1% vs market
MRF · Jan 2020: +1.3% vs market
TORNTPHARM · May 2023: +2.3% vs market
CYIENT · Apr 2023: +3.6% vs market
CUMMINSIND · Jan 2021: +3.9% vs market
BOSCHLTD · Mar 2023: +4.3% vs market
AUROPHARMA · Apr 2024: +4.9% vs market
IPCALAB · Nov 2023: +5.3% vs market
SUNPHARMA · Sep 2022: +5.3% vs market
JINDALSTEL · Sep 2025: +6.1% vs market
CIEINDIA · Dec 2022: +7.7% vs market
VOLTAS · Feb 2020: +10.2% vs market
THERMAX · Feb 2021: +11.1% vs market
CERA · Nov 2020: +13.5% vs market
COROMANDEL · Dec 2024: +14.2% vs market
UNITDSPR · Feb 2024: +14.8% vs market
RATNAMANI · May 2022: +20.7% vs market
KAJARIACER · Nov 2020: +24.8% vs market
ESCORTS · Sep 2022: +29.0% vs market
FORTIS · May 2024: +41.4% vs market
SJVN · Nov 2022: +86.4% vs market
JYOTHYLAB · Nov 2022: +87.2% vs market
Similar setups −4.5%All companies −1.6%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months

Similar setups' median
−4.5%
All companies' median
−1.6%
Beat the market
42% vs 48%

50 past situations · 50 companies · 30 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
TECHM
Technology Services		 Jan 2025 48x12% +28%−7% 0%
ULTRACEMCO
Non-Energy Minerals		 Mar 2023 29x14% +16%0% −14%
CIPLA
Health Technology		 Oct 2022 37x17% +29%0% −6%
ALKEM
Health Technology		 Nov 2023 57x14% +51%0% −8%
MRF
Consumer Durables		 Jan 2020 26x15% +14%−1% +1%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
SHREECEM
Non-Energy Minerals		 Feb 2023 40x17% +7%−2% −35%
SRF
Process Industries		 Jan 2025 74x13% +21%−1% −6%
FORTIS
Health Services		 May 2024 61x10% +73%0% +41%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, P/S and P/E. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to DR REDDYS LABORATORIES LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

EXIDE INDUSTRIESEXIDEIND
Producer Manufacturing
70%similar
operating marginP/E
CYIENTCYIENT
Technology Services
66%similar
EPS growthpromoter holding
VISHAL MEGA MARTVMM
Retail Trade
66%similar
debt/equityrevenue
RELIANCE INDUSTRIESRELIANCE
Energy Minerals
63%similar
volatilityrevenue
TATA CONSUMER PRODUCTSTATACONSUM
Consumer Non-Durables
63%similar
market capvolatility
CIPLACIPLA
Health Technology
62%similar
market caprevenue
JUBILANT PHARMOVAJUBLPHARMA
Health Technology
60%similar
operating marginrevenue growth
GRANULES INDIAGRANULES
Health Technology
53%similar
revenue growthpromoter holding

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jul '21

  1. OctPriceVolume reached 6.1x its 50-day median on 2026-10-26; price +6.6% that day.
  2. SepPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
  3. JulPriceVolume reached 5.3x its 50-day median on 2026-07-09; price -5.9% that day.
  4. JunResultsYear-on-year EPS growth turned negative.
  5. JunPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the top quartile).
  6. AprPriceVolume reached 10.2x its 50-day median on 2026-04-23; price +9.4% that day.
  7. JanPriceVolume reached 5.4x its 50-day median on 2026-01-22; price +5.2% that day.
  8. DecPeer rankSlipped to the 2nd quartile of Health Technology on operating margin (from the top quartile).
Show 22 earlier events
  1. OctPriceVolume reached 6.4x its 50-day median on 2025-10-30; price -3.9% that day.
  2. SepPeer rankMoved into the top quartile of Health Technology on operating margin (from the 2nd quartile).
  3. JunPeer rankSlipped to the 2nd quartile of Health Technology on operating margin (from the top quartile).
  4. JanValuationP/E fell below the 10th percentile of its own history to date (19.0x).
  5. DecPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the 2nd quartile).
  6. JunResultsRevenue (TTM) reached a new high of ₹28,011 cr.
  7. JunPeer rankSlipped to the 2nd quartile of Health Technology on EPS growth (from the top quartile).
  8. JunPriceVolume reached 5.2x its 50-day median on 2024-06-27; price +2.7% that day.
  9. MayValuationP/E fell below the 10th percentile of its own history to date (21.4x).
  10. AugPriceVolume reached 5.3x its 50-day median on 2023-08-09; price +3.8% that day.
  11. JulPriceRegained the 2021-07 peak, 16 months after the low.
  12. JunResultsRevenue (TTM) reached a new high of ₹24,670 cr.
  13. JunValuationP/E fell below the 10th percentile of its own history to date (19.1x).
  14. JunPeer rankMoved into the top quartile of Health Technology on ROCE (from the 3rd quartile).
  15. MayPriceVolume reached 8.9x its 50-day median on 2023-05-11; price -6.9% that day.
  16. DecPriceVolume reached 10.2x its 50-day median on 2022-12-16; price -3.6% that day.
  17. JunResultsYear-on-year EPS growth turned positive.
  18. JunPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the bottom quartile).
  19. MayPriceVolume reached 6.3x its 50-day median on 2022-05-20; price +8.1% that day.
  20. MarPriceFell 33% from the Jul 2021 peak to the Mar 2022 low.
  21. NovPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).
  22. JulPriceVolume reached 11.2x its 50-day median on 2021-07-27; price -10.5% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history60 months · 2021-12 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1135.9x₹33227 cr8.5%13.0%0.2x
2026-1035.0x₹33227 cr8.4%13.0%0.2x
2026-0931.9x₹33227 cr8.4%13.0%0.2x
2026-0823.0x₹33699 cr11.0%13.0%0.2x
2026-0722.8x₹33699 cr11.0%13.0%0.2x
2026-0627.0x₹33699 cr11.0%13.0%0.2x
2026-0519.5x₹34681 cr16.5%23.0%0.1x
2026-0419.8x₹34681 cr16.5%23.0%0.1x
2026-0318.8x₹34681 cr16.5%23.0%0.1x
2026-0218.6x₹34309 cr17.1%23.0%0.1x
2026-0117.6x₹34309 cr17.1%23.0%0.1x
2025-1218.4x₹34309 cr17.1%23.0%0.1x
2025-1118.5x₹33519 cr17.1%23.0%0.1x
2025-1017.6x₹33519 cr17.1%23.0%0.1x
2025-0918.0x₹33519 cr17.1%23.0%0.1x
2025-0818.6x₹32643 cr17.1%23.0%0.1x
2025-0718.7x₹32643 cr17.1%23.0%0.1x
2025-0618.9x₹32643 cr17.1%23.0%0.1x
2025-0519.4x₹31229 cr19.3%27.0%0.1x
2025-0418.4x₹31229 cr19.3%27.0%0.1x
2025-0317.8x₹31229 cr19.3%27.0%0.1x
2025-0217.4x₹30085 cr19.2%27.0%0.1x
2025-0119.0x₹30085 cr19.2%27.0%0.1x
2024-1221.7x₹30085 cr19.2%27.0%0.1x
2024-1118.0x₹28950 cr19.7%27.0%0.1x
2024-1019.1x₹28950 cr19.7%27.0%0.1x
2024-0920.2x₹28950 cr19.7%27.0%0.1x
2024-0821.0x₹28011 cr19.7%27.0%0.1x
2024-0720.2x₹28011 cr19.7%27.0%0.1x
2024-0619.1x₹28011 cr19.7%27.0%0.1x
2024-0521.4x₹24670 cr19.4%27.0%0.1x
2024-0422.9x₹24670 cr19.4%27.0%0.1x
2024-0322.7x₹24670 cr19.4%27.0%0.1x
2024-0223.7x₹24670 cr19.4%27.0%0.1x
2024-0122.6x₹24670 cr19.4%27.0%0.1x
2023-1221.4x₹24670 cr19.4%27.0%0.1x
2023-1121.4x₹24670 cr19.4%27.0%0.1x
2023-1019.8x₹24670 cr19.4%27.0%0.1x
2023-0920.6x₹24670 cr19.4%27.0%0.1x
2023-0820.7x₹24670 cr19.4%27.0%0.1x
2023-0720.8x₹24670 cr19.4%27.0%0.1x
2023-0619.1x₹24670 cr19.4%27.0%0.1x
2023-0534.3x₹21545 cr11.4%14.0%0.2x
2023-0437.6x₹21545 cr11.4%14.0%0.2x
2023-0335.2x₹21545 cr11.4%14.0%0.2x
2023-0232.9x₹21545 cr11.4%14.0%0.2x
2023-0133.0x₹21545 cr11.4%14.0%0.2x
2022-1232.3x₹21545 cr11.4%14.0%0.2x
2022-1134.2x₹21545 cr11.4%14.0%0.2x
2022-1033.8x₹21545 cr11.4%14.0%0.2x
2022-0933.1x₹21545 cr11.4%14.0%0.2x
2022-0832.4x₹21545 cr11.4%14.0%0.2x
2022-0731.2x₹21545 cr11.4%14.0%0.2x
2022-0633.5x₹21545 cr11.4%14.0%0.2x
2022-0537.2x₹19048 cr11.1%16.0%0.2x
2022-0435.2x₹19048 cr11.1%16.0%0.2x
2022-0336.6x₹19048 cr11.1%16.0%0.2x
2022-0234.6x₹19048 cr11.1%16.0%0.2x
2022-0136.7x₹19048 cr11.1%16.0%0.2x
2021-1241.8x₹19048 cr11.1%16.0%0.2x

Older months are in the live observatory.

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback